

Zwingenberg, Germany, 10 March 2021

Resolutions of the Annual General Meeting for the Fiscal Year 2019/2020 of BRAIN AG

- **Executive Board and Supervisory Board approved by a large majority**
- **Shareholders vote for change of company name to BRAIN Biotech AG**
- **Shareholder majority approves capital anticipatory resolutions**

At today's Annual General Meeting of B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG), the discharge of the Executive Board and Supervisory Board was approved by a large majority. All of the Annual General Meeting resolutions were passed by the shareholders, including the application for conditional and authorized capital as well as the change of the company name to BRAIN Biotech AG.

Since its foundation 28 years ago, BRAIN has evolved from a research-driven and network-oriented biotech startup into a production-oriented, integrated company with a strong scientific foundation. In the future, this development will also be reflected in the name.

Chief Executive Officer Adriaan Moelker summarizes the positive developments as: „We focused our development pipeline on seven promising R&D programs; together with our partner Roquette we have transferred our protein sweetener Brazzein to the commercialization phase; we purchased the outstanding minority stake of WeissBioTech; and we have again invested in the promising enzymatic wound-cleaning program as part of our SolasCure shareholding. Last but not least, our effective crisis management of the Covid 19 pandemic and forward-looking actions with regard to the Brexit also contributed to a successful fiscal year.”

Chief Financial Officer Lukas Linnig had presented the financial figures for the past fiscal year and said: “During the Corona pandemic, BRAIN's overall core business has proven to be sustainable. We are now working continuously to further develop the structure of the BRAIN Group and are investing significantly in our own research and development as well as in our future products.”

The shareholders' meeting elected three candidates to the Supervisory Board, including Professor Dr.-Ing. Wiltrud Treffenfeldt and Stephen Catling, both of whom had been members of the Supervisory Board on the basis of a court appointment since October 14, 2020 until this shareholders' meeting. Dr. Anna Carina Eichhorn, a member of the Supervisory Board since 2017 and currently Deputy Chairwoman, was re-elected to the Board by the shareholders' meeting.

The Chairman of the Supervisory Board, Dr. Georg Kellinghusen, who chaired the Annual General Meeting, was very satisfied with the developments in the past financial year: "Following some significant management changes, BRAIN has now restored management continuity. The company has made good progress in the past year in developing itself in regards to business, organization and strategy. The company is well positioned to achieve its medium-term goals."

At the time of voting on the agenda items, between 11,367,594 and 13,505,974 of the capital stock divided into 19,861,360 registered shares were represented. The participation rate in voting, measured against the capital stock, was hence between 57.23% and 68.00%.

The detailed voting results as well as the presentation of the Management Board and all other documents relating to the Annual General Meeting are available on the BRAIN AG website at <https://www.brain-biotech.com/investors/annual-general-meetings/agm-fy-2019-20>

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.



Picture: Chairman of the Supervisory Board Dr. Georg Kellinghusen, CEO Adriaan Moelker and CFO Lukas Linnig (from left to right) during the digital Annual General Meeting for fiscal year 2019/20 (Copyright BRAIN AG)

Press release and image for download: <https://www.brain-biotech.com/press>

Further press image files: <https://www.brain-biotech.com/press-images>

Further information:

Annual Report 2019/20: <https://www.brain-biotech.com/investors/financial-publications/2019-20>

Presentations 2021 Annual General Meeting:

<https://www.brain-biotech.com/investors/annual-general-meetings/agm-fy-2019-20>

Financial calendar: www.brain-biotech.com/investors/financial-calendar

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the area of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms and natural substances from complex biological systems, in order to make them utilizable in an industrial context. The innovative solutions and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model stands on two pillars. The BioScience segment comprises mainly research and development business with industrial partners, and the company's own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products. As part of a growth-oriented industrialization strategy, in February 2016 BRAIN AG became the first bioeconomy company to be listed on the Prime Standard of the Frankfurt Stock Exchange.

Contact Investor Relations

Michael Schneiders
Head of Investor Relations
Phone: +49 6251 9331-86
Email: mis@brain-biotech.com

Media Contact

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Follow BRAIN on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG)